Department of Pathology and Laboratory Medicine Dartmouth Health.
Geisel School of Medicine at Dartmouth, Lebanon, NH.
Am J Surg Pathol. 2024 Apr 1;48(4):487-496. doi: 10.1097/PAS.0000000000002175. Epub 2024 Jan 8.
Despite significant advances in their molecular pathogenesis, skeletal vascular tumors remain diagnostically challenging due to their aggressive radiologic appearance and significant morphologic overlap. Within the epithelioid category and at the benign end of the spectrum, recurrent FOS/FOSB fusions have defined most epithelioid hemangiomas, distinguishing them from epithelioid hemangioendothelioma and angiosarcoma. More recently, the presence of EWSR1/FUS :: NFATC1/2 fusions emerged as the genetic hallmark of a novel group of unusual vascular proliferations, often displaying epithelioid morphology, with alternating vasoformative and solid growth, variable atypia, reminiscent of composite hemangioendothelioma. In this study, we further our understanding and morphologic spectrum of NFATC -fusion positive vascular neoplasms by describing 9 new cases, including soft tissue locations and novel fusion partners. Combining with the initial cohort of 5 cases, a total of 14 patients were analyzed, showing slight female predilection and an age range of 10 to 66 (mean 42 y). Twelve patients had solitary lesions, while 2 had multifocal polyostotic (pelvic bones) disease. Overall, 12 lesions were intra-osseous and 2 in soft tissue. By targeted RNA Fusion panels or FISH, there were 6 cases of EWSR1::NFATC1 , 4 EWSR1::NFATC2 , 2 FUS::NFATC2 , 1 EWSR1 rearrangement, and 1 with a novel FABP4::NFATC2 fusion. Follow-up was available in 4 patients. One patient experienced 2 local recurrences, 11 and 15 years postdiagnosis, and one patient experienced progressive disease despite multimodality treatment (curettings, embolization, radiation) over 3 years. In summary, our extended investigation confirms that NFATC -related fusions define a distinct group of vascular neoplasms with variable architecture, epithelioid phenotype, and cytologic atypia, commonly located in the bone, occasionally multifocal and with potential for local recurrence and aggressive behavior but no metastatic potential. Molecular analysis is recommended in diagnostically challenging cases with atypical histology to exclude malignancy.
尽管在分子发病机制方面取得了重大进展,但由于其侵袭性的影像学表现和显著的形态重叠,骨骼血管肿瘤在诊断上仍然具有挑战性。在上皮样类别中,在良性范围内,复发性 FOS/FOSB 融合已定义了大多数上皮样血管瘤,将其与上皮样血管内皮细胞瘤和血管肉瘤区分开来。最近,EWSR1/FUS :: NFATC1/2 融合的存在成为一组新型不寻常血管增生的遗传标志,这些增生通常表现出上皮样形态,具有交替的血管形成和实体生长、可变异型性,类似于复合血管内皮细胞瘤。在这项研究中,我们通过描述 9 例新病例,包括软组织部位和新的融合伙伴,进一步了解和扩展了 NFATC-融合阳性血管肿瘤的形态谱。结合最初的 5 例病例,共分析了 14 例患者,显示出轻微的女性倾向和 10 至 66 岁(平均 42 岁)的年龄范围。12 例患者为单发病变,2 例为多灶性多骨(骨盆)疾病。总体而言,12 例病变位于骨内,2 例位于软组织内。通过靶向 RNA 融合面板或 FISH,有 6 例 EWSR1::NFATC1,4 例 EWSR1::NFATC2,2 例 FUS::NFATC2,1 例 EWSR1 重排,1 例具有新型 FABP4::NFATC2 融合。4 例患者有随访。1 例患者分别在诊断后 11 年和 15 年经历了 2 次局部复发,1 例患者尽管进行了 3 年的多模式治疗(刮除术、栓塞术、放疗),但仍出现进行性疾病。总之,我们的扩展研究证实,NFATC-相关融合定义了一组具有不同结构、上皮样表型和细胞异型性的血管肿瘤,常见于骨骼,偶尔为多灶性,并有局部复发和侵袭性行为的潜在风险,但无转移潜能。在具有非典型组织学的诊断挑战性病例中,建议进行分子分析以排除恶性肿瘤。